(Circulation. 1997;96:1282-1290.)
© 1997 American Heart Association, Inc.
Articles |
From the Institute of Clinical Pharmacology (R.H.B., S.M.B.-B., L.P., M.B., J.C.F.) and Departments of Cardiology (R.P.B., A.M.) and Pathology (R.N.), Medical School, Hannover, Germany.
Background We investigated whether L-arginine induces regression of preexisting atheromatous lesions and reversal of endothelial dysfunction in hypercholesterolemic rabbits, whether similar effects can be obtained by cholesterol-lowering therapy with lovastatin, and which mechanism leads to these effects.
Methods and Results Rabbits were fed 1%
cholesterol for 4 weeks and 0.5% cholesterol
for an additional 12 weeks. Two groups of cholesterol-fed
rabbits were treated with L-arginine (2.0% in drinking
water) or lovastatin (10 mg/d) during weeks 5 through 16.
Systemic nitric oxide (NO) formation was assessed as the urinary
excretion rates of nitrate and cGMP in weekly intervals.
Cholesterol feeding progressively reduced urinary nitrate
excretion to
40% of baseline (P<.05) and increased
plasma concentrations of asymmetrical dimethylarginine (ADMA), an
endogenous NO synthesis inhibitor. Dietary
L-arginine reversed the reduction in plasma
L-arginine/ADMA ratio and partly restored urinary excretion
of nitrate and cGMP (each P<.05 vs cholesterol)
but did not change plasma cholesterol levels.
L-Arginine completely blocked the progression of carotid
intimal plaques, reduced aortic intimal thickening, and preserved
endothelium-dependent vasodilator function.
Lovastatin treatment reduced plasma cholesterol
by 32% but did not improve urinary nitrate or cGMP excretion or
endothelium-dependent vasodilation.
Lovastatin had a weaker inhibitory effect on
carotid plaque formation and aortic intimal thickening than
L-arginine. L-Arginine inhibited but
lovastatin potentiated superoxide radical generation in the
atherosclerotic vascular wall.
Conclusions Dietary L-arginine improves NO-dependent vasodilator function in cholesterol-fed rabbits and completely blocks the progression of plaques via restoration of NO synthase substrate availability and reduction of vascular oxidative stress. Lovastatin treatment has a weaker inhibitory effect on the progression of atherosclerosis and no effect on vascular NO elaboration, which may be due to its stimulatory effect on vascular superoxide radical generation.
Key Words: endothelium-derived factors endothelium free radicals lipoproteins plaque
This article has been cited by other articles:
![]() |
B. A. Nier, L. S. Harrington, M. J. Carrier, and P. D. Weinberg Evidence for a specific influence of the nitrergic pathway on the peripheral pulse waveform in rabbits Exp Physiol, April 1, 2008; 93(4): 503 - 512. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Lucke, N. Kanzelmeyer, K. Chobanyan, D. Tsikas, D. Franke, M. J. Kemper, J. H.H. Ehrich, and A. M. Das Elevated asymmetric dimethylarginine (ADMA) and inverse correlation between circulating ADMA and glomerular filtration rate in children with sporadic focal segmental glomerulosclerosis (FSGS) Nephrol. Dial. Transplant., February 1, 2008; 23(2): 734 - 740. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. J. Pope, L. Druhan, J. E. Guzman, S. P. Forbes, V. Murugesan, D. Lu, Y. Xia, L. G. Chicoine, N. L. Parinandi, and A. J. Cardounel Role of DDAH-1 in lipid peroxidation product-mediated inhibition of endothelial NO generation Am J Physiol Cell Physiol, November 1, 2007; 293(5): C1679 - C1686. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. P. Brandes Roads to Dysfunction: Argininase II Contributes to Oxidized Low-Density Lipoprotein-Induced Attenuation of Endothelial NO Production Circ. Res., October 27, 2006; 99(9): 918 - 920. [Full Text] [PDF] |
||||
![]() |
R. K Oka, A. Szuba, J. C Giacomini, and J. P Cooke A pilot study of l-arginine supplementation on functional capacity in peripheral arterial disease Vascular Medicine, November 1, 2005; 10(4): 265 - 274. [Abstract] [PDF] |
||||
![]() |
T. Hayashi, P. A. R. Juliet, H. Matsui-Hirai, A. Miyazaki, A. Fukatsu, J. Funami, A. Iguchi, and L. J. Ignarro L-citrulline and L-arginine supplementation retards the progression of high-cholesterol-diet-induced atherosclerosis in rabbits PNAS, September 20, 2005; 102(38): 13681 - 13686. [Abstract] [Full Text] [PDF] |
||||
![]() |
V Achan, H. Ho, C Heeschen, M Stuehlinger, J. Jang, M Kimoto, P Vallance, and J. Cooke ADMA regulates angiogenesis: genetic and metabolic evidence Vascular Medicine, February 1, 2005; 10(1): 7 - 14. [Abstract] [PDF] |
||||
![]() |
R. H. Boger Asymmetric Dimethylarginine, an Endogenous Inhibitor of Nitric Oxide Synthase, Explains the "L-Arginine Paradox" and Acts as a Novel Cardiovascular Risk Factor J. Nutr., October 1, 2004; 134(10): 2842S - 2847S. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. N. Kim, D. W. Christianson, and A. M. Traish Role of Arginase in the Male and Female Sexual Arousal Response J. Nutr., October 1, 2004; 134(10): 2873S - 2879S. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. H Boger The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor Cardiovasc Res, October 1, 2003; 59(4): 824 - 833. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Niebauer, A. J. Maxwell, P. S. Lin, D. Wang, P. S. Tsao, and J. P. Cooke NOS inhibition accelerates atherogenesis: reversal by exercise Am J Physiol Heart Circ Physiol, July 11, 2003; 285(2): H535 - H540. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. P. Cooke, K. Sydow, J. Chen, and P. Huang A Peculiar Result and a Fanciful Hypothesis Regarding L-Arginine * Arterioscler. Thromb. Vasc. Biol., June 1, 2003; 23(6): 1128 - 1128. [Full Text] [PDF] |
||||
![]() |
D Tousoulis, G J Davies, C Tentolouris, T Crake, G Goumas, C Stefanadis, and P Toutouzas Effects of L-arginine on flow mediated dilatation induced by atrial pacing in diseased epicardial coronary arteries Heart, May 1, 2003; 89(5): 531 - 534. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. Alper and R. D. Mattes Peanut Consumption Improves Indices of Cardiovascular Disease Risk in Healthy Adults J. Am. Coll. Nutr., April 1, 2003; 22(2): 133 - 141. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Chen, P. Kuhlencordt, F. Urano, H. Ichinose, J. Astern, and P. L. Huang L-Arginine on Atherosclerosis in ApoE Knockout and ApoE/Inducible NO Synthase Double-Knockout Mice Arterioscler. Thromb. Vasc. Biol., January 1, 2003; 23(1): 97 - 103. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Tousoulis, C. Antoniades, C. Tentolouris, G. Goumas, C. Stefanadis, and P. Toutouzas L-Arginine in cardiovascular disease: dream or reality? Vascular Medicine, August 1, 2002; 7(3): 203 - 211. [Abstract] [PDF] |
||||
![]() |
R. Baetta, M. Camera, C. Comparato, C. Altana, M. D. Ezekowitz, and E. Tremoli Fluvastatin Reduces Tissue Factor Expression and Macrophage Accumulation in Carotid Lesions of Cholesterol-Fed Rabbits in the Absence of Lipid Lowering Arterioscler. Thromb. Vasc. Biol., April 1, 2002; 22(4): 692 - 698. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Zoccali, F. A. Benedetto, R. Maas, F. Mallamaci, G. Tripepi, L. Salvatore Malatino, and R. Boger Asymmetric Dimethylarginine, C-Reactive Protein, and Carotid Intima-Media Thickness in End-Stage Renal Disease J. Am. Soc. Nephrol., February 1, 2002; 13(2): 490 - 496. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. A. Walker, E. McGing, I. Fisher, R. H. Boger, S. M. Bode-Boger, G. Jackson, J. M. Ritter, and P. J. Chowienczyk Endothelium-dependent vasodilation is independent of the plasma L-arginine/ADMA ratio in men with stable angina: Lack of effect of oral l-arginine on endothelial function, oxidative stress and exercise performance J. Am. Coll. Cardiol., August 1, 2001; 38(2): 499 - 505. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. K. Thakur, T. Hayashi, D. Sumi, H. Kano, T. Tsunekawa, and A. Iguchi HMG-CoA reductase inhibitor stabilizes rabbit atheroma by increasing basal NO and decreasing superoxide Am J Physiol Heart Circ Physiol, July 1, 2001; 281(1): H75 - H83. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. H. Boger, S. M. Bode-Boger, P. S. Tsao, P. S. Lin, J. R. Chan, and J. P. Cooke An endogenous inhibitor of nitric oxide synthase regulates endothelial adhesiveness for monocytes J. Am. Coll. Cardiol., December 1, 2000; 36(7): 2287 - 2295. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. P. Cooke Does ADMA Cause Endothelial Dysfunction? Arterioscler. Thromb. Vasc. Biol., September 1, 2000; 20(9): 2032 - 2037. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Behr-Roussel, A. Rupin, S. Simonet, E. Bonhomme, S. Coumailleau, A. Cordi, B. Serkiz, J.-N. Fabiani, and T. J. Verbeuren Effect of Chronic Treatment With the Inducible Nitric Oxide Synthase Inhibitor N-Iminoethyl-L-Lysine or With L-Arginine on Progression of Coronary and Aortic Atherosclerosis in Hypercholesterolemic Rabbits Circulation, August 29, 2000; 102(9): 1033 - 1038. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. H. Boger, K. Sydow, J. Borlak, T. Thum, H. Lenzen, B. Schubert, D. Tsikas, and S. M. Bode-Boger LDL Cholesterol Upregulates Synthesis of Asymmetrical Dimethylarginine in Human Endothelial Cells : Involvement of S-Adenosylmethionine-Dependent Methyltransferases Circ. Res., July 21, 2000; 87(2): 99 - 105. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. H. Boger, S. M. Bode-Boger, K. Sydow, D. D. Heistad, and S. R. Lentz Plasma Concentration of Asymmetric Dimethylarginine, an Endogenous Inhibitor of Nitric Oxide Synthase, Is Elevated in Monkeys With Hyperhomocyst(e)inemia or Hypercholesterolemia Arterioscler. Thromb. Vasc. Biol., June 1, 2000; 20(6): 1557 - 1564. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. D. Fike, M. R. Kaplowitz, L. A. Rehorst-Paea, and L. D. Nelin L-Arginine increases nitric oxide production in isolated lungs of chronically hypoxic newborn pigs J Appl Physiol, May 1, 2000; 88(5): 1797 - 1803. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Fujiwara, T. Osanai, T. Kamada, T. Katoh, K. Takahashi, and K. Okumura Study on the Relationship Between Plasma Nitrite and Nitrate Level and Salt Sensitivity in Human Hypertension : Modulation of Nitric Oxide Synthesis by Salt Intake Circulation, February 29, 2000; 101(8): 856 - 861. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Schwemmer, O. Sommer, R. Koeckerbauer, and E. Bassenge Cardiovascular Dysfunction in Hypercholesterolemia Associated With Enhanced Formation of ATI-Receptor and of Eicosanoids Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 2000; 5(1): 59 - 68. [Abstract] [PDF] |
||||
![]() |
J. Niebauer, J.o. Dulak, J. R. Chan, P. S. Tsao, and J. P. Cooke Gene transfer of nitric oxide synthase: Effects on endothelial biology J. Am. Coll. Cardiol., October 1, 1999; 34(4): 1201 - 1207. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Leiper and P. Vallance Biological significance of endogenous methylarginines that inhibit nitric oxide synthases Cardiovasc Res, August 15, 1999; 43(3): 542 - 548. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Palomaki, K. Malminiemi, O. Malminiemi, and T. Solakivi Effects of Lovastatin Therapy on Susceptibility of LDL to Oxidation During {alpha}-Tocopherol Supplementation Arterioscler. Thromb. Vasc. Biol., June 1, 1999; 19(6): 1541 - 1548. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. P Cooke The 1998 Nobel prize in Medicine: clinical implications for 1999 and beyond Vascular Medicine, May 1, 1999; 4(2): 57 - 60. [PDF] |
||||
![]() |
H. Miyazaki, H. Matsuoka, J. P. Cooke, M. Usui, S. Ueda, S. Okuda, and T. Imaizumi Endogenous Nitric Oxide Synthase Inhibitor : A Novel Marker of Atherosclerosis Circulation, March 9, 1999; 99(9): 1141 - 1146. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. T. KIELSTEIN, R. H. BÖGER, S. M. BODE-BÖGER, J. SCHÄFFER, M. BARBEY, K. M. KOCH, and J. C. FRÖLICH Asymmetric Dimethylarginine Plasma Concentrations Differ in Patients with End-Stage Renal Disease: Relationship to Treatment Method andAtherosclerotic Disease J. Am. Soc. Nephrol., March 1, 1999; 10(3): 594 - 600. [Abstract] [Full Text] |
||||
![]() |
K. M. Channon, H. Qian, V. Neplioueva, M. A. Blazing, E. Olmez, G. A. Shetty, S. A. Youngblood, J. Pawloski, T. McMahon, J. S. Stamler, et al. In Vivo Gene Transfer of Nitric Oxide Synthase Enhances Vasomotor Function in Carotid Arteries From Normal and Cholesterol-Fed Rabbits Circulation, November 3, 1998; 98(18): 1905 - 1911. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. H. Boger, S. M. Bode-Boger, W. Thiele, A. Creutzig, K. Alexander, and J.u. C. Frolich Restoring vascular nitric oxide formation by L-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease J. Am. Coll. Cardiol., November 1, 1998; 32(5): 1336 - 1344. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. A. Quyyumi Does acute improvement of endothelial dysfunction in coronary artery disease improve myocardial ischemia?: A double-blind comparison of parenteral D- and L-Arginine J. Am. Coll. Cardiol., October 1, 1998; 32(4): 904 - 911. [Abstract] [Full Text] [PDF] |
||||
![]() |
J o. Koglin, T. Glysing-Jensen, J. S. Mudgett, and M. E. Russell Exacerbated Transplant Arteriosclerosis in Inducible Nitric Oxide–Deficient Mice Circulation, May 26, 1998; 97(20): 2059 - 2065. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Kalinowski, L. W. Dobrucki, V. Brovkovych, and T. Malinski Increased Nitric Oxide Bioavailability in Endothelial Cells Contributes to the Pleiotropic Effect of Cerivastatin Circulation, February 26, 2002; 105(8): 933 - 938. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Baetta, M. Camera, C. Comparato, C. Altana, M. D. Ezekowitz, and E. Tremoli Fluvastatin Reduces Tissue Factor Expression and Macrophage Accumulation in Carotid Lesions of Cholesterol-Fed Rabbits in the Absence of Lipid Lowering Arterioscler. Thromb. Vasc. Biol., April 1, 2002; 22(4): 692 - 698. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1997 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |